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Muscle coenzyme Q10 (CoQ10 or ubiquinone) deﬁciency has been identiﬁed in more than 20 patients with presumed autosomal-reces-
sive ataxia. However, mutations in genes required for CoQ10 biosynthetic pathway have been identiﬁed only in patients with infantile-
onset multisystemic diseases or isolated nephropathy. Our SNP-based genome-wide scan in a large consanguineous family revealed a
locus for autosomal-recessive ataxia at chromosome 1q41. The causative mutation is a homozygous splice-site mutation in the aarF-do-
main-containing kinase 3 gene (ADCK3). Five additional mutations in ADCK3were found in three patients with sporadic ataxia, includ-
ing one known to have CoQ10 deﬁciency inmuscle. All of the patients have childhood-onset cerebellar ataxia with slow progression, and
three of six have mildly elevated lactate levels. ADCK3 is a mitochondrial protein homologous to the yeast COQ8 and the bacterial UbiB
proteins, which are required for CoQ biosynthesis. Three out of four patients tested showed a low endogenous pool of CoQ10 in their
ﬁbroblasts or lymphoblasts, and two out of three patients showed impaired ubiquinone synthesis, strongly suggesting that ADCK3 is
also involved in CoQ10 biosynthesis. The deleterious nature of the three identiﬁed missense changes was conﬁrmed by the introduction
of them at the corresponding positions of the yeast COQ8 gene. Finally, a phylogenetic analysis shows that ADCK3 belongs to the family
of atypical kinases, which includes phosphoinositide and choline kinases, suggesting that ADCK3 plays an indirect regulatory role in
ubiquinone biosynthesis possibly as part of a feedback loop that regulates ATP production.Introduction
Recessive ataxias are a heterogeneous group of inherited
neurodegenerative disorders that affect the cerebellum or
the spinocerebellar and sensory tracts of the spinal cord.
Several recessive ataxias, including Friedreich ataxia
(FRDA [MIM 229300]), appear to be due to defective mito-
chondrial proteins. In FRDA and sideroblastic anemia/
ataxia (ASAT [MIM 301310]), the defective proteins are in-
volved in iron-sulfur cluster biogenesis, whereas in sensory
ataxic neuropathy with dysarthria and ophthalmoparesis
(SANDO [MIM 607459]) and in infantile-onset spinocere-
bellar ataxia (IOSCA [MIM 271245]), the defective proteins
control mitochondrial DNA homeostasis.1–5 In addition,
recently reported forms of recessive ataxia are associated
with muscle coenzyme Q10 (CoQ10) deﬁciency
6,7 [MIM
607426] and might also involve genes encoding mito-
chondrial proteins because CoQ10 is synthesized in mito-
chondria. CoQ10 deﬁciency causes mitochondrial dysfunc-
tion because CoQ10 carries electrons from complex I and
complex II to complex III in the mitochondrial respiratory
chain. Several forms of human coenzyme Q10 deﬁciencies,
all characterized by infantile encephalomyopathy, renalfailure, or both, have recently been attributed tomutations
in speciﬁc CoQ10 biosynthetic proteins (COQ2, PDSS2,
and PDSS1).8–10 Given that these were not null mutations,
they should allow the production of either partially func-
tional proteins or reduced levels of normal proteins, sup-
porting the view that complete block of CoQ10 synthesis
would not be viable.
The genes involved in CoQ (ubiquinone) synthesis were
identiﬁed by analysis of yeast and bacterial complementa-
tion groups of ubiquinone-deﬁcient strains designated
coq1-coq10 and ubiA-ubiH, respectively. Most of them
(COQ 1–3, COQ 5–7, Ubi A, Ubi E–H) correspond to spe-
ciﬁc enzymatic steps of ubiquinone synthesis.11,12 Here,
we describe the ﬁrst recessive ataxia due to mutations in
a COQ8-UbiB homolog, whichmost likely has an ancestral
regulatory, rather than enzymatic, function.
Material and Methods
Subjects
We obtained clinical evaluation, blood samples, and skin biopsies
after written informed consent as deﬁned by the local ethics com-
mittees of the University Hospital of Algiers, Strasbourg, and the1Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, CNRS/INSERM/Universite´ Louis Pasteur, et Colle`ge de France, Chaire de ge´ne´tique humaine,
67404 Illkirch, France; Hoˆpitaux Universitaires de Strasbourg, Strasbourg, F-67000 France; 2Service de Neurologie, Centre Hospitalo-Universitaire Musta-
pha, Algiers 16000, Algeria; 3Department of Neurology, Columbia University Medical Center, New York, NY 10032 USA; 4Departamento de Microbiologia -
ICB-II - Universidade de Sa˜o Paulo, 05508-900, Sa˜o Paulo, SP, Brasil; 5Service de Neurologie, Hoˆpital Ait Idir, Algiers, Algeria; 6Institut Pasteur d’Alger, El
Hamma, Algiers, Algeria; 7Service de Neurologie, Hoˆpitaux Universitaires de Strasbourg, 67091 Strasbourg, France; 8Department of Neurology, University
of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
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Children’s Hospital of Philadelphia. Affected individuals from
family 1 were referred for autosomal recessive cerebellar ataxia,
and DNA testing for Friedreich ataxia and AOA1 mutations was
performed prior to linkage analysis. Primary ﬁbroblasts from
skin biopsies were obtained from patients 3, 5, and 6, and immor-
talized lymphoblastoid cell lines were obtained from patients 3, 5,
and 7.
Linkage Analysis
Genome-wide homozygosity mapping was performed with the
GeneChip Human Mapping 10K 2.0 Xba Array from Affymetrix
(Affymetrix, Santa Clara, CA). Sample processing and labeling
were performed according to the manufacturer’s instructions (Af-
fymetrix Mapping 10K 2.0 Assay Manual, Version 1.0, 2004). Hy-
bridization was performed with a GeneChip Hybridization oven
640, washed with the GeneChip Fluidics Station 450, and scanned
with a GeneChip Scanner 3000. Single-nucleotide polymorphism
(SNP) allele calls were generated by the GeneChip DNA Analysis
Software version 3.0.2 (GDAS). Regions of homozygosity were de-
ﬁned by the presence of more than 25 consecutive homozygous
SNPs and analyzed on HomoSNP software developed to visualize
shared homozygous regions in consanguineous families (software
available on request from plewniak@igbmc.u-strasbg.fr). The re-
gion of homozygosity by descent segregating with the disease
was further analyzed with highly polymorphic microsatellite
markers as described elsewhere.13
Mutational Analysis
Mutational analysis was performed by PCR and direct sequencing
of the 14 coding exons and the adjacent intronic junctions of hu-
man ADCK3 gene (NM_020247; primers and conditions available
on request). PCR products were puriﬁed on Montage PCR96
Cleanup Plates (Millipore, Bedford, MA) and used in sequencing
reactions with the ABI BigDye Terminator Kit (Applied Biosys-
tems), which were subsequently run on an ABI PRISM 3100 Ge-
netic Analyzer. Computational analyses of mutations were carried
out with Seqscape 2.5 software (Applied Biosystems). Parental seg-
regation of the identiﬁed mutations was investigated in all avail-
able family members. ADCK3 exon 8 and 11 splicing was analyzed
by RT-PCR. Total RNA was extracted from primary ﬁbroblasts or
immortalized lymphoblastoid cells via Trizol according to the
manufacturer’s protocol (Invitrogen). Total RNA was reverse tran-
scribed with the Superscript II kit (Invitrogen). PCR ampliﬁcation
was performed with primers located in exon 10 and exon 15 (for-
ward 50-CACCTGATTGACGTGCTGAG-30, reverse 50-ATCTTC
TCGGTGGTGCTCTG-30) and in exon 7 and exon 12 (forward
50-CAACCCCCACCTGGCTAAG-30, reverse 50-GGGGTCATAGAA
GAAGTTGGA-30). PCR products were separated on a 2% agarose
gel and eluted with the Nucleospin extract II kit (Macherey-Nagel)
before sequencing with the PCR forward and reverse primers.
ADCK4 mRNA Expression Analyses
by Quantitative RT-PCR
Relative expression levels of ADCK4 mRNA were determined by
real-time PCR with the LightCycler 480 protocol (Roche Biosci-
ences) and a set of primers located in exon 13 and exon 15 (for-
ward 50-CGGGAGTTTGGGACAGAGT-30, reverse 50-CCGACCCAA
AGTCGTAAGG-30). ADCK4 mRNA expression was normalized to
b-actin or to RPLP0 mRNA expression. Data were analyzed with
the 2DDCt method, and values are expressed as the mean of two
separate experiments performed in duplicate.662 The American Journal of Human Genetics 82, 661–672, MarchCoQ10 Determination and CoQ10 Biosynthesis Assay
Coenzyme Q10 (CoQ10) in both ﬁbroblasts and lymphoblasts (2–
3 3 106 cells) was extracted in hexane and measured by high-per-
formance liquid chromatography with electrochemical detection
(HPLC-EQ).8,9 An aliquot of the sample was used for protein deter-
mination with the BCA protein assay kit (Pierce). The results were
expressed in ng of CoQ10/mg-protein. CoQ10 biosynthesis in ﬁbro-
blasts was measured by incorporation of labeled parahydroxyben-
zoate (14C-PHB) (450 Ci/mol).8,9 After 48 hr of incubation with
14C-PHB (0.02 mCi/ml) in the culture medium, radiolabeled
CoQ10 was extracted by hexane, isolated by HPLC with a C18 re-
verse-phase column, and collected and quantiﬁed in a scintillation
counter. An aliquot of the sample was used for protein determina-
tion with the BCA protein assay kit (Pierce). The results were ex-
pressed in DPM/mg-protein/day.
Respiratory-Chain Enzyme Activities
To measure the complex activities, ﬁbroblasts were suspended in
cold PBS (4–12 3 106 cells) and sonicated for 10 s to disrupt the
membranes. An aliquot of the samplewas used for protein determi-
nation with the BCA protein assay kit (Pierce). Complexes I and III
(CIþIII) activity was measured by observation of the reduction of
cytochrome c (cyt c) at 550 nm.14 In brief, 4–123 104 cells were in-
cubated at 30C in amedium containing 10mMKH2PO4 (pH 7.8),
2 mM EDTA, 1 mg/ml BSA, 500 mM KCN, and 100 mM cyt c. After
2 min of incubation, the reaction was started by addition of 200
mM NADH, and the increase of absorbance is observed for an ad-
ditional 2 min. The residual activity in the presence of rotenone
(10 mg/ml) was subtracted from total activity. The results were ex-
pressed in nmol of reduced cyt c/min/mg-protein. Complex IV (or
COX) activity wasmeasured by observation of the reduction of cyt
c at 550 nm.14 In brief, 8–24 3 104 cells were incubated at 30C in
a medium containing 10 mM KH2PO4 (pH 6.5), 0.25 M sucrose,
1mg/ml BSA, and 0.1% reduced cyt c, and the reactionwas observed
for 3 min. For inhibition of the reaction, 500 mM KCN was used.
The results were expressed in nmol of oxidized cyt c/min/mg-pro-
tein. Citrate synthase (CS) activitywasmeasured after the reduction
of 100 mM 5,50-dithiobis(2-nitrobenzoic acid) (DTNB) at 412 nm
(30C) in the presence of 8–24 3 104 cells, 300 mM acetyl CoA,
10 mM Tris-Cl (pH ¼ 7.5), and 500 mM oxaloacetic acid.14 The re-
sults were expressed in nmol of TNB/min/mg-protein. The results
of CIþIII and COX activities were normalized to CS activity.
Complexes II and III activity was measured by observation of
the reduction of cytochrome c at 550 nm.14 In brief, 4–12 3 104
cells were incubated at 30C in medium containing 50 mM
KH2PO4/K2HPO4 (pH 7.5), 20mM succinate, 1.5mMKCN, and 2.5
mM rotenone KCN. After 10 min of incubation, the reaction was
started by the addition of 50 mM cyt c, and increase of absorbance
was observed for 2 min. The results were expressed in nmol of re-
duced cyt c/min/mg-protein and normalized to CS activity.
Complex III activity was measured by observation of the reduc-
tion of cytochrome c at 550 nm.14 In brief, 8–24 3 104 cells were
incubated at 30C in a medium containing 25 mM KH2PO4
(pH 7.2), 5 mM MgCl2, 2.5 mg/ml BSA, 50 mg/ml Rotenone, and
15 mM reduced cyt c. After 3 min of incubation, the reaction was
started by the addition of 350 mM ubiquinol, and the reaction
was followed for 2 min. The results were expressed in nmol of ox-
idized cyt c/min/mg-protein and normalized to CS activity.
Phylogenetic Tree and Multiple Alignment
The Uniprot protein-sequence database was searched with
ADCK3_HUMAN (647 residues) as a query, and a multiple2008
alignment of the detected homologous sequences was constructed
with the PipeAlign tool.15 A structural multiple alignment of the
catalytic core domain of representative kinases has been previ-
ously proposed,16 in which six atypical kinases and 25 protein ki-
nases were aligned. For each of the six structurally aligned atypical
kinase sequences, we downloaded from the PFAM17 database seed
alignments containing atypical kinase core domains, including 16
sequences of phosphatidylinositol phosphate kinase (PIPK)
(PF01504), eight sequences of transient receptor potential (TRP)
channel kinase domain (ChaK) (PF02816), 42 sequences of
the phosphoinositide 3-kinase catalytic subunit (PI3K-PI4K)
(PF00454), seven sequences of the actin-fragmin kinase (AFK)
(PF09192), and 33 sequences of choline kinase (CKA-2)
(PF01633). In addition, we downloaded a PFAM seed alignment
of protein kinases (PF00069) containing 54 sequences. All col-
lected seed alignments and the alignment obtained with ADCK3_
HUMAN as a query were concatenated and aligned on the basis of
known protein-kinase motifs. The resulting multiple alignment of
221 sequences wasmanually reﬁned in the SeqLab editor (Wiscon-
sin package, Accelrys).
A phylogenetic tree was constructed with the neighbor-joining
algorithm implemented in the phylowin program18 from the
aligned sequences via the global gap-removal option and 500
bootstrap replicates. The iTOL tool19 was used to generate the phy-
logenetic tree.
Yeast Experiments
The coq8 yeast point mutants were created by PCR with speciﬁc
primers containing the related humanmutations. These new yeast
coq8 alleles were then excised and cloned at the HindIII site of
YIp352. These constructions were sequenced and the mutations
conﬁrmed. The recombinant plasmids were linearized with the in-
ternal NcoI site ofURA3, and the linear fragment was used to trans-
form the yeast strain W303DelCOQ8 by homologous recombina-
tion.20 Puriﬁed individual transformants, the null mutant, and the
wild-type W303-1A (Dr. R. Rothstein, Columbia University) were
checked for growth on YPEG (1% yeast extract, 2% peptone, 2%
ethanol, 3% glycerol, 2% agar) and YPD (1% yeast extract, 2% pep-
tone, 2% glucose, 2% agar). Oxygen consumption and peroxide
production were measured in yeast spheroplasts, isolated from
cells grown on 2% galactose-rich media as described elsewhere.21
Exogenous coenzyme Q6 was added to a ﬁnal concentration of
15 mM in YPEG liquid media,22 and growth was monitored by
Figure 1. Genotyping and Imaging Re-
sults of ARCA2 Families
(A) SNP results of family 1 for the chromo-
some 1q41-q42 region. Graphic interface
(HomoSNP software) for visualization of
shared regions of homozygosity in consan-
guineous families. The top horizontal bar
indicates the position of recessive-ataxia
loci and genes. Subsequent bars indicate
individual results of the children repre-
sented on the left. The regions with more
than 25 consecutive homozygous SNP are
in black. The regions of heterozygosity
are in gray. The four affected siblings in
family 1 share a region of homozygosity
by descent on chromosome 1q41-q42. The
AXPC1 locus is centromeric to this region
of homozygosity.
(B) Microsatellite analysis at chromosome
1q41-q42 in all available family 1 members.
Markers are indicated on the left and are
organized from top to bottom in the cen-
tromeric to telomeric order. Results of the
four critical SNPs that define the two re-
combination boundaries are also indicated.
Parental haplotypes linked with the dis-
ease are boxed. The region of homozygos-
ity by descent is shaded in gray. Haplotype
segregation confirms linkage between the
1q41-q42 locus and the disease in this
family and defines a 12.6 Mb critical inter-
val.
(C) Sagittal T1-weighted brain magnetic
resonance imaging of patient 4 (family 1)
and patient 5 (family 2) showing cerebellar
atrophy and mild cerebral atrophy.
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absorbance at 600 nm measurements for 10 days, at the end of
which samples were taken and plated on YPD to check for possible
contamination.
Results
ADCK3 Mutations in ARCA2, a Novel
Ataxia Syndrome
We performed linkage studies on a large consanguineous
Algerian family with four individuals affected with child-
hood-onset cerebellar ataxia (family 1). We analyzed the
four patients and one healthy sibling with 10K Affymetrix
SNP arrays and identiﬁed, with a novel display program
(Figure 1A), a unique region of homozygosity shared by
all affected whereas the healthy sibling was heterozygous.
The smallest region of overlap spanned 12.6 Mb on chro-
mosome 1q41-q42 and did not overlap with the posterior
column ataxia and retinitis pigmentosa locus (AXPC1
[MIM 609033]),23 located immediately centromeric
(Figure 1A). The study of a dense set of microsatellite
markers from the region in all available members of the
family, including the father and two additional healthy
siblings, conﬁrmed linkage to the 1q41-42 locus (Figure 1B)
with LOD-score calculation yielding a maximum 2-point
value of 3.9 (theta¼ 0). Because four genes encoding mito-
chondrial proteins are already known to cause recessive
ataxia when defective,1–4 we prioritized sequencing of
genes on the basis of the mitochondrial localization of
their encoded products. We found a homozygous donor
splice-site mutation (c.1398þ2T/C, Figure 2A) in intron
11 of ADCK3 (NM_020247; aarF-domain-containing ki-
nase 3; also known as CABC1 [MIM 606980]) that was
not present in 480 control chromosomes including 192
of North African origin. We carried out RT-PCR analysis
Figure 2. Altered Splicing of ADCK3
Exon 11 in Family 1 and Exon 8 in Family 4
(A) Genomic sequence of ADCK3 exon-in-
tron 11 boundary of a control individual
and of the father and patient 3 of family
1. The patient is homozygous for the donor
splice-site mutation 1398þ2T/C. The
healthy father is heterozygous for this mu-
tation.
(B) Analysis of RT-PCR products of patient 3
fibroblasts. The 1398þ2T/C mutation af-
fects exon 11 splicing and results in the
production of two major bands on agarose
gel, of 442 and 654 bp, respectively, and
the product obtained from a control indi-
vidual has a size of 584 bp. A faint band mi-
grating between products 1 and 2 was
shown by sequencing to correspond to het-
eroduplexes of products 1 and 2 (data not
shown).
(C) Sequence of product 1 after elution
from agarose gel. Product 1 corresponds
to skipping of exon 11 leading to a frame-
shift with a predicted truncated protein
(p.Asp420TrpfsX40).
(D) Sequence of product 2 after elution
from agarose gel. Product 2 corresponds
to the use of two cryptic splice sites in in-
tron 11 leading to the insertion of 68 and
70 nucleotides (nt), respectively. The se-
quence of the two alternative products is
indicated above the chromatogram. The re-
spective position of the two cryptic donor
splice sites is indicated below the chro-
matogram (underlined). In both cases, 21
amino acids are inserted before an in frame
stop codon (circled) leading to a predicted
truncated protein (Ile467AlafsX22).
(E) Analysis of RT-PCR products of patient 7 lymphoblastoid cells. The c.993C/T mutation partially affects exon 8 splicing and results in
the production of an abnormal product of 487 bp on agarose gel whereas only a normal product of 628 bp is seen in control lymphoblastoid
cells. The abnormal product corresponds to skipping of exon 8 leading to an in-frame deletion of 47 amino acids (p.Lys314_Gln360 del).
The faint intermediate band was shown by sequencing to correspond to heteroduplexes (data not shown).
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Table 1. ADCK3 Mutations and Clinical Features in ARCA2 Patients
Family 1 Family 2 Family 3 Family 4
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6a Patient 7
Sex M M M F M M F
Origin Algeria Algeria Algeria Algeria Algeria USA France/Algeria
Mutation Homo
c.1398þ2T/C
Homo
c.1398þ2T/C
Homo
c.1398þ2T/C
Homo
c.1398þ2T/C
Homo
c.500_521
delinsTTG
Hetero
c.[1541A/G]
þ [1750_1752
delACC]
Hetero c.[993C/
T] þ [1645G/A]
Location Intron 11 Intron 11 Intron 11 Intron 11 Exon 3 Exons 13 and 15 Exons 8 and 14
Predicted amino
acid change
p.[Asp420Trp
fsX40,Ile467
AlafsX22]
p.[Asp420Trp
fsX40,Ile467
AlafsX22]
p.[Asp420Trp
fsX40,Ile467
AlafsX22]
p.[Asp420Trp
fsX40,Ile467
AlafsX22]
p.Gln167
LeufsX36
p.[Tyr514Cys]
þ[Thr584 del]
p.[Lys314_Gln360
del]þ [Gly549Ser]
Age of onset 11 4 7 8 4 5 3
Disease duration 31 34 29 21 14 12 27
Cerebellar ataxia þ þ þ þ þ þ þ
Cerebellar atrophy þ þ þ þ þ þ NA
Disability stage 3 3 3 3 3 3 3
Exercise intolerance  þ þ þ  NA NA
Reflexes Absent
ankle jerks
Normal Brisk Brisk Normal Brisk Brisk
Hoffmann’s sign    þ  þ 
Babinski sign       
Pes cavus þ þ  þ þ  þ
Mental retardation  Mild   Mild  Moderate (IQ: 54)
Lactic acidosis in
mmol/l
NA 3.3
(n ¼ 0.5–2.2)
2.9
(n ¼ 0.5–2.2)
1.8–7.8
(n ¼ 0.5–2.2)
1.29
(n ¼ 0.5–2.2)
0.7
(n ¼ 0.5–2.2)
0.98 (n ¼ 1–1.7)
EMG Normal Normal Normal Normal Mild axonal
neuropathy
NA Normal
Muscle biopsy NA NA NA NA NA Mild non
specific changes
NA
Miscellaneous Gynecomastia;
feet and thumbs
in dystonic
position
Mild hearing loss
The following abbreviations are used: M, male; F ¼ female; NA, not available; and EMG, electromyography. Disability stage grade 3: moderate, unable to
run, limited walking without aid, in a scale from 0 (no signs or symptoms handicap) to 7 (bedridden).
a Patient 6 is individual 8 in reference 6.of ADCK3 from ﬁbroblast RNA of patient 3 and found three
splice variants expressed from the mutant allele (Figures
2B–2D). In the shorter variant, exon 10 was skipped result-
ing in a frameshift (p.Asp420TrpfsX40) (Figure 2C). In the
other variants, two cryptic splice sites in intron 11 were
used, resulting in insertions of 68 and 70 nucleotides,
with a stop codon after 21 residues (p.Ile467AlafsX22)
(Figure 2D).
Three hundred and ﬁfty-three families with non-Frie-
dreich ataxia were analyzed either by homozygosity map-
ping at 1q41-q42 or by direct sequencing of ADCK3 coding
exons and ﬂanking sequences. We identiﬁed ﬁve addi-
tional mutations (one single-amino-acid deletion, one
truncating mutation, two missense mutations, and a pre-
dicted disruption of an SRp55 exonic splice enhancer) in
three sporadic cases (Table 1). The three single-amino-
acid changes affect conserved residues of the ADCK3 pro-
tein (Figure 3) and were absent from 480 control chromo-
somes. Their pathogenicity was subsequently conﬁrmed
(see below). The nucleotide change in the predicted exonicThe Asplice enhancer24,25 in exon 8 was also absent from 480
control chromosomes, and its consequence was analyzed
by RT-PCR from the patient’s lymphoblastoid cell line.
ADCK3 transcript analysis revealed an abnormal product
corresponding to skipping of exon 8 (Figure 2E) and
leading to an in-frame deletion of 47 amino acids
(p.Lys314_Gln360 del).
All affected individuals with mutations in ADCK3
had childhood-onset gait ataxia and cerebellar atrophy
(Figure 1C), with slow progression and few associated fea-
tures (Table 1). Some patients had brisk tendon reﬂexes
and Hoffmann’s sign. Three patients had mild psycho-
motor retardation, and one patient had mild axonal de-
generation of the sural nerve. None had renal dysfunc-
tion. Exercise intolerance and elevated serum lactate
was present in three patients. Because cerebellar ataxia
dominates the clinical presentation, we propose to
name this entity ARCA2 (autosomal-recessive cerebellar
ataxia 2), following the recent identiﬁcation of ARCA1
[MIM 610743].26merican Journal of Human Genetics 82, 661–672, March 2008 665
Coenzyme Q10 Deﬁciency in ARCA2 Patients
ADCK3 is a mitochondrial protein27 that has yeast (ABC1/
COQ8) and bacterial (UbiB) homologs known to be in-
Figure 3. Conservation of Amino Acids
Mutated in ARCA2 Patients among
ADCK3–ADCK4 Protein Sequences
SPTREMBL accession numbers are indicated
on the left. cabc1_human and q96d53_hu-
man correspond to ADCK3 and ADCK4, re-
spectively. The following abbreviations are
used: Xenla, Xenopus laevis; brare, Brachyda-
nio rerio; tetng, Tetraodon nigroviridis;
drome, Drosophila melanogaster; caeel, Cae-
norhabditis elegans; dicdi, Dictyostelium dis-
coideum; yeast, Saccharomyces cerevisiae;
schpo, Schizosaccharomyces pombe; arath,
Arabidopsis thaliana; plaf7, Plasmodium fal-
ciparum; and jansc, Jannaschia sp. Amino
acid numbering corresponds to human
ADCK3. Dots and stars indicate variable de-
grees of phylogenetic conservation. Con-
served amino acids are colored according
to amino acid class (ClustalX). The N-termi-
nal motif conserved in all members of the
ADCK family (KxGK at positions 276–279)
and the kinase motif VII (DFG at positions
507–509) are overlined in red. Nontruncat-
ing mutations identified in ARCA2 patients
(p.Tyr514Cys, p.Gly549Ser, and p.Thr584
del) are indicated with arrows.
(A) ClustalX sequence alignments of ADCK-
specific N-terminal domain.
(B) ClustalX sequence alignments of ADCK3–
ADCK4-specific C-terminal domain.
volved in coenzyme Q (ubiquinone)
synthesis on the basis of yeast and bac-
terial complementation groups of ubi-
quinone-deﬁcient strains.11,22 Patient
6 was previously reported to have
marked CoQ10 deﬁciency in muscle
(12.6 mg of CoQ10/g of fresh tissue;
normal values 27.6 mg/g 5 4.4);6
therefore, identiﬁcation of ADCK3
mutations in this individual indicated
that ADCK3 is also involved in CoQ
synthesis in humans. To conﬁrm this
result in the absence of muscle biop-
sies from the other patients, we ana-
lyzed CoQ10 levels and synthesis in
cultured skin ﬁbroblast or lymphoblas-
toid cell lines from patients 3, 5, 6, and
7 and found moderate but signiﬁcant
reduction in three (Table 2) and nor-
mal level in patient 3. In addition, be-
cause CoQ10 is the electron carrier
from respiratory complexes I and II
to complex III, measuring of the combined activity of these
enzymes assesses endogenous pools of CoQ10 in mito-
chondria. These activities were signiﬁcantly reduced in
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Table 2. Coenzyme Q10 and Respiratory-Chain Enzyme Activities in ARCA2 Patients
Patient 3 Patient 5 Patient 6 Patient 7
Patient with
COQ2 Mutationsa
Patient with PDSS2
Mutationsb Controls
CoQ10 levels in fibroblasts
(ng/mg-protein)
69.0 36.9 5 6.5 29.7 NA 24.85 1.0 13.05 1.7 58.55 4.1 n ¼ 15
CoQ10 levels in lymphoblasts
(ng/mg-protein)
68.2 57.9 5 13.9 NA 48.5 5 2.9 NA NA 62.25 2.8, n ¼ 3
CoQ10 biosynthesis assay in
fibroblastsc (CoQ10 DPM/
mg-protein/day)
41085 52 2825 20065 15 NA 13495 37 7895 22 35695 255, n ¼ 5
CIþCIII/COX 11.82 6.99 7.76 NA NA NA 13.865 1.27, n ¼ 3
CIþCIII/CS 6.36 3.70 4.13 NA NA NA 8.035 0.67, n ¼ 3
CIþCIII/CS fold increase
after addition of CoQ2
1.88 2.15 2.47 NA NA NA 1.265 0.07, n ¼ 3
CIIþCIII/CS 0.46 0.37 0.24 NA NA NA 0.465 0.02, n ¼ 2
CIII/CS 0.65 0.83 0.62 NA NA NA 0.815 0.18, n ¼ 2
Abnormal values are shown in bold. When experiments were done more than once, values are given as means5 standard error of the mean. The following
abbreviations are used: CI, complex I (NADH ubiquinone oxidoreductase); CII, complex II (succinate ubiquinone oxidoreductase); CIII, complex III (ubiq-
uinol cytochrome c oxidoreductase); COX, cytochrome c oxidase; CS, citrate synthase; CoQ2, coenzyme Q2 (strong rescue by CoQ2 is indicative of CoQ de-
ficiency); and DPM, decays per min.
a This patient with COQ2 mutations was previously described.8
b This patient with PDSS2 mutations was previously described.9
c By incorporation of 14C-PHB (parahydroxybenzoate).the ﬁbroblasts of patients 5 and 6 and moderately reduced
in those of patient 3. Moreover, addition of a short-chain
quinone analog increased signiﬁcantly complexes IþIII ac-
tivity in the ﬁbroblasts of all patient tested, an indirect
demonstration of CoQ10 deﬁciency in these cells (Table
2). ADCK3 mutations were therefore associated with
CoQ10 deﬁciency, although the defect was very mild in un-
affected tissues of ARCA2 patients.
ADCK3 Belongs to a Superfamily of Ancestral Protein
and Nonprotein Kinases
ADCK proteins possess the conserved protein-kinase mo-
tifs28 corresponding to regions required for ATP binding
and for phosphotransfer reaction (the ‘‘universal core’’
consisting of motifs I, II, VIb, and VII) but do not conserve
all of the usual kinase motifs (Figure 4A). In order to gain
insights on the origin of the ADCK proteins, we analyzed
the sequence of 61 prokaryotic and eukaryotic ADCK ho-
mologs and compared them to the sequence of 54 protein
kinases and 106 atypical kinases. On the basis of the phy-
logenetic analysis of the ‘‘universal core’’ of the ADCK ki-
nases (Figure 4B, and Figure S2 available online) and of
the absence of the classical C-terminal motifs (Figure 4A),
we propose that ADCKs belong to the so-called ‘‘atypical
kinases’’ of the protein-kinase-like superfamily described
by Scheeff and Bourne.16 This superfamily comprises
both nonprotein kinases, such as phosphoinositide and
choline kinases, and atypical protein kinases, such as the
actin-fragmin kinases (Figure 4B and Figure S2). The
ADCK family comprises ﬁve paralogs in human (ADCK1-
5). ADCK3 and ADCK4 are highly similar and appear to re-
sult from a gene duplication in vertebrates. In contrast,
ADCK1, 2, and 5 have split from ADCK3 and 4 very early
during evolution because all eukaryotes and several, but
not all, gram-negative bacteria possess at least one repre-The Asentative of each subgroup (Figure S2). Yeast ABC1/Coq8
is the ortholog of ADCK3 and 4, whereas bacterial UbiB
is more similar to the ADCK1–ADCK5 subgroup. The ‘‘uni-
versal core’’ of ADCKs comprises a highly conserved lysine
that binds the alpha phosphate and two highly conserved
aspartates that bind the magnesium ions chelated by ATP.
Interestingly, the p.Tyr514Cys mutation in patient 6 is lo-
cated immediately after the second aspartate (DFGmotif or
motif VII, Figure 4A), strongly supporting a pathogenic ef-
fect of this amino acid change. The p.Gly549Ser is located
outside the ‘‘universal core’’ but is highly conserved among
members of the ADCK3/ADCK4 subgroup (Figure 3), also
supporting a pathogenic effect of the p.Gly549Ser change
in patient 7. Gly549 is part of a C-terminal highly con-
served segment, which is divergent not only from the clas-
sical protein-kinase domain, but also among the different
subgroups of the ADCK family (Figure 4B and Figure S2),
suggesting that proteins from each subgroup support a
distinct function. On the other hand, all ADCK proteins
share a common N-terminal domain (with invariable
residues Lys276, Glu278, and Gln279; Figures 3 and 4A),
which is absent from all other protein and nonprotein
kinases and appears speciﬁcally related with ubiquinone
metabolism.
Nontruncating Mutations Introduced in the Yeast
ADCK3 Homolog Result in Impaired Respiration
For assessment of their pathogenicity, the three mutations
resulting in single-amino-acid change (p.Tyr514Cys;
p.Gly549Ser; and p.Thr584 del) were introduced on the
yeast coq8 mutant background. Yeast coq mutants grow
on glucose but display impaired growth on nonferment-
able carbon source (ethanol and glycerol), indicating a de-
fect in respiration that can be rescued by exogenous CoQ6
supplementation.22 They produce high levels of H2O2merican Journal of Human Genetics 82, 661–672, March 2008 667
and display impaired oxygen consumption. The corre-
sponding missense changes and single-amino-acid dele-
tion (Phe372Cys, Gly407Ser, and Ser444del) were intro-
duced into a yeast COQ8 expression plasmid by site-
directed mutagenesis. Transformation of yeast Delcoq8 by
mutant plasmids failed to restore growth on selective respi-
ratory medium, whereas the wild-type sequence did, con-
ﬁrming the deleterious nature of the mutations
(Figure 5A). Interestingly, replacement of Phe372 by the
homologous human amino acid Tyr (corresponding to
Tyr514) in the expression plasmid resulted in rescue
when transfected in the Delcoq8 mutant (Figure 5A), indi-
cating that these two aromatic residues are interchange-
able, a view also supported by their equal occurrence dur-
ing evolution at this position (Figure 3). Moreover,
oxygen consumption, H2O2 production, and rescue by ex-
ogenous CoQ6 were similar in Delcoq8 mutants and Del-
coq8 yeast transformed with plasmids carrying the deleteri-
ous missense mutations (Figures 5B–5D). However, rescue
by exogenous CoQ6 was not as efﬁcient in coq8 mutants
as in coq7 or coq2 mutants (Figure 5D), which are directly
impaired in ubiquinone synthesis.
Reduced Expression of the ADCK4 Paralog Correlates
with CoQ10 Deﬁciency in Fibroblasts
In order to test whether compensatory mechanisms regu-
late ADCK4 expression in the case of ADCK3 deﬁciency,
we compared ADCK4 mRNA expression by quantitative
RT-PCR in three patient ﬁbroblasts and in four control ﬁ-
broblasts. ADCK4 mRNA level was normal in patient 3
but, paradoxically, was mildly decreased in patients 5
and 6 (Figure 6). Because patient 3 ﬁbroblasts had normal
CoQ10 levels and onlymoderately reduced complexes IþIII
activity compared to ﬁbroblasts of patients 5 and 6 (Table
2), it appears that transcriptional downregulation of
ADCK4 parallels CoQ10 levels in patient ﬁbroblasts. The re-
sults suggest that ADCK4, the closest paralog of ADCK3,
might also be involved in regulation of CoQ10 synthesis.
Further studies are needed to validate this observation
and assess its relevance in affected tissues.
Discussion
Familial cerebellar ataxia associated with muscle CoQ10
deﬁciency was ﬁrst reported in 2001.29 Genes coding for
Figure 4. Domain Organization and
Phylogeny of ADCK Proteins
(A) Motif conservation in typical protein
kinases and in ADCK proteins. Consensus
of the eight most conserved motifs of the
typical protein kinases are indicated on
top. Motifs that share homology with
ADCKs motifs are indicated in red. Consen-
sus of ADCK motifs are indicated below,
with amino acid positions corresponding
to human ADCK3. ADCK domains are de-
picted on the diagram as follows: blue rect-
angle, N-terminal domain conserved
among all members of the ADCK family
and containing the KxGQ motif; red ovals,
the position of the conserved kinase mo-
tifs; yellow rectangle, C-terminal domain
specific for each ADCK subgroups. The posi-
tion of single-amino-acid changes found in
ARCA2 patients is indicated at the bottom.
(B) Phylogenetic tree of typical and atypi-
cal protein kinases. Typical protein kinases
are clustered in a single group. ADCK pro-
teins are clustered in four groups. The
UbiB group corresponds to the bacterial
ADCKs and to the chloroplastic bacterial-
like ADCKs. The following abbreviations
are used: PI4KII, phosphatidylinositol 4 ki-
nase type 2; AFK, actin-fragmin kinase;
ChaK, TRP channel kinase; PIPK, Phospha-
tidylinositol Phosphate Kinase; and PI3K-
PI4K, phosphatidylinositol 3 and 4 kinases
and related protein kinases.
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enzymes involved in CoQ synthesis were candidates for
this new form of ataxia. These genes have been identiﬁed
by analysis of yeast and bacterial complementation
groups of ubiquinone-deﬁcient strains designated coq1-
coq10 and ubiA-ubiH, respectively; all have at least one
homolog in humans, supporting the concept that CoQ
synthesis is a conserved pathway in all species. However,
the ﬁrst human mutations reported in genes encoding
CoQ biosynthetic enzymes (PDSS1 and PDSS2, corre-
sponding to COQ1 and COQ2, catalyze the ﬁrst two spe-
ciﬁc steps of CoQ synthesis, and COQ2 catalyzes the sec-
ond speciﬁc step) were identiﬁed in patients with severe
Figure 5. Coq8 Null Yeast Phenotype Was Not Rescued by Transfection with Plasmids Carrying the Nontruncating Mutations Iden-
tified in ARCA2 Patients
(A) Serial dilutions of the wild-type AW303, the coq8 null mutant (Dcoq8 ¼ Delcoq8), and the mutant transformed with yeast wild-type
COQ8 or with yeast coq8 nontruncating mutations were spotted on rich glucose (YPD) and rich ethanol/glycerol (YPEG) plates. Growth on
nonfermentable carbon source (YPEG) was not restored by mutant coq8 but was rescued by the wild-type sequence and by the F372Y con-
struct corresponding to the replacement of F372 by the homologous human amino acid (Y at the human position 514).
(B) Oxygen consumption is impaired in coq8 null mutant (Dcoq8) and in Dcoq8 yeast transformed with plasmids carrying the deleterious
mutations.
(C) H2O2 production is elevated in coq8-deficient strains. Impaired oxygen consumption and increased H2O2 production are indicative of
respiratory-chain dysfunction.
(D) Exogenous coenzyme Q (CoQ6) respiratory-growth rescue. Rescue was similar in Dcoq8 strain and in Dcoq8 yeast transformed with
mutated plasmids and was less efficient than rescue of coq7 and coq2 yeast mutants.
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infantile-onset encephalomyopathy, renal failure, or
both,8–10 suggesting that direct impairment of CoQ10 syn-
thesis might not be associated with the milder forms of
cerebellar ataxia. In fact, muscle CoQ10 deﬁciency was
found in some patients with ataxia with ocular apraxia
type 130 (AOA1 [MIM 208920]), which thus became the
ﬁrst form of genetically deﬁned ataxia to be associated
with partial ubiquinone deﬁciency.31 The relationship be-
tween aprataxin, the nuclear protein defective in AOA1,
and muscle CoQ10 deﬁciency is not known. To our knowl-
edge, our identiﬁcation of mutations in ADCK3, homolo-
gous to yeast COQ8 and to bacterial UbiB, documents
for the ﬁrst time that the defect of a mitochondrial protein
involved in CoQ10 synthesis can cause an almost pure
form of autosomal-recessive cerebellar ataxia, which we
named ARCA2. ARCA2 patients may be distinguished
from other recessive ataxias by the presence of cerebellar
atrophy with history of exercise intolerance in childhood
and elevated serum lactate at rest or after moderate exer-
cise. After excluding the index family, ARCA2 appears to
be a rare cause of ataxia among European, U.S., and North
African patients. The fact that we found ADCK3 muta-
tions in a patient with previously reported muscle
CoQ10 deﬁciency
6 and the fact that other ARCA2 patients
had moderate CoQ10 deﬁciency in their ﬁbroblast or lym-
phoblastoid cell lines suggest that ADCK3 is involved in
CoQ synthesis, supporting the view that ADCK3, COQ8,
and UbiB are functional homologs. CoQ10 deﬁciency in
ARCA2 patients raises the possibility of supplementation
therapy. So far, only one patient (patient 6)6 has been
Figure 6. Absence of ADCK4 Induction in ADCK3-Deficient
Fibroblasts
ADCK4 mRNA levels in control fibroblasts (n ¼ 4) and in pa-
tients 3, 5, and 6 fibroblasts were measured by quantitative
real-time PCR. Expression levels of ADCK4 in patients 5 and 6
were slightly reduced. This slight reduction was not dependent
on the type of housekeeping reference RNA used: (A) RPLP0 (ri-
bosomal protein P0); (B) b-actin. Graphs represent means 5
standard deviation (SD) of two independent experiments per-
formed in duplicates.
treated with doses of CoQ10 from 60 to 700 mg/day
over 8 yr. The patient reported mild subjective im-
provement, and stabilization of the cerebellar ataxia
was observed on examination. In three families, the
identiﬁcation of ADCK3 mutations was made solely
on the basis of the ataxic phenotype and without
knowledge of muscle CoQ10 level, indicating that
ARCA2 corresponds to a homogeneous syndrome, dis-
tinct from syndromes due to direct enzymatic block of
CoQ10 synthesis. The milder presentation of ARCA2
patients compared to patients with enzymatic block
of CoQ10 synthesis might be explained both by the re-
dundancy of ADCK members in the human genome
and by an indirect role of ADCK3 in CoQ10 synthesis.
An indirect, regulatory role is supported by the simi-
larity of the ADCKs with members of the superfamily of
the atypical kinases. This ﬁnding leaves open the possibil-
ity that ADCK substrates might be protein or nonprotein
molecules, making their identiﬁcation an even more dif-
ﬁcult task. The indirect role of ADCKs in CoQ synthesis is
also supported by the delayed rescue by exogenous CoQ6
of the yeast mutant strain abc1/coq8, compared to rescue
of the coq2 or coq7 mutants, which are defective in para-
hydroxybenzoate-polyprenyl transferase and 5-deme-
thoxyubiquinol hydroxylase, respectively.32,33 The de-
layed rescue of the abc1/coq8 mutants compared to coq2
or coq7 mutants suggests that ABC1/COQ8 may also act
downstream of CoQ production and may regulate addi-
tional pathways. Given the central role of CoQ in ATP
synthesis, it is tempting to speculate that ADCKs regulate
CoQ synthesis by phosphorylating substrates as part of
a feedback loop that controls the level of ATP produced.
In support of this hypothesis, it was observed that over-
expression of ABC1/COQ8 has the ability to rescue other
coq mutants. Indeed, overexpression of ABC1/COQ8 res-
cued the growth of coq10 mutant by doubling the
amount of mitochondrial coenzyme Q,34 and it also sup-
pressed a missense mutant of coq9.35 Furthermore, in coq
mutants there is global depletion of COQ3, COQ4,
COQ6, COQ7, and COQ9, which appear to be part of
a protein complex,20,36 but not of COQ8, indicating
that it is not part of the complex but affects its stability.36
Despite the independent identiﬁcation of aarF-domain-
containing kinases (ADCKs) in 1998,28,37 their substrates
have remained elusive. The identiﬁcation of mutations in
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one ADCK member in cerebellar ataxia patients will cer-
tainly stimulate research on this family of ancestral ki-
nases, in order to decipher the corresponding regulatory
network and its relation with CoQ biosynthesis.
Supplemental Data
Two ﬁgures can be found with this article online at http://www.
ajhg.org/.
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